Key Highlights
- Shares of Vir Biotechnology (VIR) reached a 52-week peak Tuesday following the announcement of a significant collaboration with Astellas Pharma targeting prostate cancer treatment VIR-5500.
- The partnership includes $335 million in initial and near-term compensation, with potential milestone payments reaching $1.37 billion.
- Phase 1 clinical results demonstrated that VIR-5500 monotherapy achieved an 82% PSA50 response rate among patients receiving the highest doses.
- Fourth quarter results surpassed projections with a loss of 31 cents per share compared to the forecasted 41 cents, while revenue reached $64.07 million against expectations of $23.18 million.
- Evercore ISI upgraded its price target on VIR to $18 from $12, continuing with an Outperform rating.
Vir Biotechnology (VIR) experienced remarkable market performance Tuesday. Shares climbed nearly 60% during premarket hours, establishing a fresh 52-week high following several announcements made between Monday and Tuesday morning.
The driving force? A substantial multi-billion dollar collaboration with Japan-based pharmaceutical company Astellas Pharma, updated Phase 1 clinical results for its primary oncology candidate, and fourth quarter financial performance that exceeded analyst projections.
Vir will collect $335 million through upfront and near-term payments as part of the agreement. This comprises $240 million in direct cash payment alongside a $75 million equity investment priced at a 50% premium above current market value.
Following the initial payment, Vir stands to receive up to $1.37 billion through additional milestone achievements as VIR-5500 progresses through clinical development stages.
According to the collaboration terms, Astellas will take the lead on commercializing VIR-5500 throughout the United States, with both companies sharing profits and losses on an equal basis.
VIR-5500 represents a PSMAxCD3 dual-masked bispecific antibody currently undergoing investigation for treating advanced metastatic castration-resistant prostate cancer (mCRPC).
Clinical Data Generates Enthusiasm
The Phase 1 results unveiled Monday demonstrated that VIR-5500 monotherapy maintained a favorable safety profile among patients who had undergone multiple previous treatment regimens — a particularly challenging patient population.
Among patients receiving the highest dose levels, PSA50 reductions occurred in 82% of participants, while PSA90 reductions appeared in 53%. Within the evaluable patient group, 45% demonstrated objective responses according to RECIST criteria.
Activity correlated with dose levels across the entire treatment population, with PSMA-PET imaging confirming tumor reduction across various lesions, including those with visceral metastases.
Vir has finalized monotherapy dose-escalation studies in late-line mCRPC patients and continues advancing combination dose-escalation trials with enzalutamide in earlier-line patient populations.
The company intends to initiate monotherapy dose-expansion cohorts during Q2 2026, with pivotal Phase 3 studies scheduled to begin in 2027.
Financial Performance and Operating Capital
Regarding financial results, Vir reported a Q4 loss of 31 cents per share, outperforming the consensus projection of a 41-cent loss. Revenue totaled $64.07 million, substantially exceeding the $23.18 million analysts had anticipated.
Including the capital infusion from Astellas, Vir projects sufficient resources to sustain operations through Q2 2028.
From a technical perspective, the stock traded 12.3% above its 20-day SMA and 14.5% above its 100-day SMA entering Tuesday’s session. RSI registered at a neutral 50, while MACD suggested modest bearish momentum below its signal line.
Evercore ISI responded promptly to the developments. The firm increased its price target on VIR to $18 from $12 while maintaining its Outperform rating.
Evercore characterized the Astellas partnership as confirmation of VIR-5500’s clinical promise and highlighted the safety profile as differentiated relative to competing bispecific antibodies under development. The firm indicated the agreement may signal positive prospects for Vir’s broader bispecific pipeline.
Analyst price targets on VIR currently span from $12 to $26, with shares trading at $7.43 before the premarket rally commenced.
